Pfizer begins study of oral drug for prevention of COVID-19
Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus. The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop an easy-to-administer antiviral pill for COVID-19.
View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-begins-study-covid-19-antiviral-drug-2021-09-27/